Top
Main

All Outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Supplementary Data — Zinc for COVID-19: real-time meta analysis of 49 studies
Covid Analysis, December 2022
https://c19early.org/zmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Derwand 79% 0.21 [0.03-1.47] death 1/141 13/377 CT​2 Improvement, RR [CI] Treatment Control Derwand 82% 0.18 [0.07-0.54] hosp. 4/141 58/377 CT​2 Thomas (RCT) -44% 1.44 [0.36-5.71] hosp. 5/58 3/50 Thomas (RCT) 12% 0.88 [0.67-1.16] recov. time 58 (n) 50 (n) Aldwihi 24% 0.76 [0.51-1.08] hosp. 53/199 184/539 Asimi 97% 0.03 [0.00-0.44] ventilation 0/270 9/86 CT​2 Asimi 99% 0.01 [0.00-0.16] hosp. 0/270 24/86 CT​2 Asimi 100% 0.00 [0.00-0.08] severe case 0/270 51/86 CT​2 Mayberry 53% 0.47 [0.33-0.65] death 938 (n) 1,090 (n) Mayberry 64% 0.36 [0.27-0.47] ventilation 938 (n) 1,090 (n) Mayberry 60% 0.40 [0.31-0.52] ICU 938 (n) 1,090 (n) Mayberry 58% 0.42 [0.33-0.54] death/v/ICU 938 (n) 1,090 (n) Mayberry 85% 0.15 [0.10-0.22] progression 938 (n) 1,090 (n) Abdallah (DB RCT) 30% 0.70 [0.36-1.31] death 15/231 22/239 Abdallah (DB RCT) 38% 0.62 [0.37-0.99] death/ICU 24/231 40/239 Abdallah (DB RCT) 54% 0.46 [0.23-0.88] ICU 12/231 27/239 Abdallah (DB RCT) 42% 0.58 [0.39-0.87] oxygen 31/231 55/239 Abdallah (DB RCT) 23% 0.77 [0.65-0.91] oxygen 108/231 145/239 Abdallah (DB RCT) 29% 0.71 [0.57-0.88] no recov. 82/231 120/239 Abdallah (DB RCT) 14% 0.86 [0.80-0.93] no recov. 180/231 216/239 Abdallah (DB RCT) 69% 0.31 [0.03-2.61] hosp. 1/85 4/100 Abdallah (DB RCT) 33% 0.67 [0.59-0.75] hosp. time 146 (n) 134 (n) Abdallah (DB RCT) 25% 0.75 [0.65-0.87] recov. time 85 (n) 100 (n) Carlucci 38% 0.62 [0.46-0.84] death/HPC 54/411 119/521 Carlucci 18% 0.82 [0.54-1.25] ventilation 29/411 62/521 Carlucci 23% 0.77 [0.53-1.10] ICU 38/411 82/521 Krishnan 18% 0.82 [0.62-1.09] death 31/58 61/94 Yao 34% 0.66 [0.41-1.07] death 73/196 21/46 Frontera (PSM) 37% 0.63 [0.44-0.91] death 121/1,006 424/2,467 CT​2 Frontera (PSM) 24% 0.76 [0.60-0.96] death 121/1,006 424/2,467 CT​2 Abd-Elsalam (RCT) 1% 0.99 [0.30-3.31] death 5/96 5/95 Abd-Elsalam (RCT) 34% 0.66 [0.19-2.26] ventilation 4/96 6/95 Abd-Elsalam (RCT) 6% 0.94 [0.55-1.62] no recov. 20/96 21/95 Abd-Elsalam (RCT) 4% 0.96 [0.86-1.08] hosp. time 96 (n) 95 (n) Rosenthal -16% 1.16 [1.05-1.28] death n/a n/a Darban (RCT) 33% 0.67 [0.14-3.17] progression 2/10 3/10 ICU patients CT​2 Darban (RCT) 6% 0.94 [0.84-1.06] ICU 10 (n) 10 (n) ICU patients CT​2 Patel (DB RCT) 20% 0.80 [0.15-4.18] death 2/15 3/18 Mulhem 46% 0.54 [0.43-0.68] death 256/1,596 260/1,623 Gadhiya -41% 1.41 [0.69-2.57] death 21/54 34/229 Al Sulaiman (ICU) 36% 0.64 [0.37-1.10] death 23/82 32/82 ICU patients Al Sulaiman (ICU) 48% 0.52 [0.29-0.92] death 19/82 31/82 ICU patients Al Sulaiman (ICU) -25% 1.25 [0.84-1.87] ICU 82 (n) 82 (n) ICU patients Al Sulaiman (ICU) -6% 1.06 [0.85-1.33] hosp. time 82 (n) 82 (n) ICU patients Elavarasi 65% 0.35 [0.24-0.56] death 486 (n) 1,201 (n) Assiri (ICU) -81% 1.81 [0.41-6.97] death 10/60 4/58 ICU patients Kaplan (RCT) -14% 1.14 [0.08-16.6] ventilation 1/14 1/16 CT​2 Kaplan (RCT) -14% 1.14 [0.08-16.6] ICU 1/14 1/16 CT​2 Kaplan (RCT) -14% 1.14 [0.08-16.6] hosp. 1/14 1/16 CT​2 Zangeneh (ICU) -21% 1.21 [0.51-2.90] death n/a n/a ICU patients Alahmari 30% 0.70 [0.63-0.78] hosp. time 130 (n) 847 (n) Doocy 41% 0.59 [0.19-1.85] death 3/28 21/116 Louca 1% 0.99 [0.93-1.06] cases Mahto 37% 0.63 [0.22-1.49] IgG+ 10/38 83/651 Holt 7% 0.93 [0.59-1.44] cases 21/750 425/14,477 Abdulateef 13% 0.87 [0.38-1.97] hosp. 7/111 23/317 Seet (CLUS. RCT) 50% 0.50 [0.34-0.75] symp. case 33/634 64/619 OT​1 Seet (CLUS. RCT) 27% 0.73 [0.55-0.97] cases 300/634 433/619 OT​1 Israel 100% 0.00 [0.00-0.89] hosp. case control CT​2 Bagheri 60% 0.40 [0.04-3.53] severe case 33 (n) 477 (n) Bagheri 41% 0.59 [0.14-1.61] hosp. 4/33 167/477 Gordon 68% 0.32 [0.01-7.87] death 0/104 1/96 Gordon 85% 0.15 [0.02-0.58] symp. case 2/104 9/96 Kumar 20% 0.80 [0.21-2.99] death 6/75 3/30 Nimer -25% 1.25 [0.87-1.77] hosp. 41/326 178/1,822 Nimer -13% 1.13 [0.81-1.56] severe case 46/326 214/1,822 Shehab 47% 0.53 [0.19-1.47] severe case 4/65 22/188 Citu 18% 0.82 [0.12-5.68] severe case 2/74 2/61 CT​2 Stambouli (DB RCT) 68% 0.32 [0.03-2.95] symp. case 1/59 3/56 Stambouli (DB RCT) 5% 0.95 [0.29-3.10] cases 5/59 5/56 Stambouli (DB RCT) 21% 0.79 [0.73-0.84] viral load 59 (n) 56 (n) Adrean -12% 1.12 [0.74-1.70] cases 30/2,111 80/6,315 Sharif 40% 0.60 [0.46-0.77] severe case n/a n/a Sharif 97% 0.03 [0.01-0.22] severe case n/a n/a Zinc COVID-19 outcomes c19early.org/z Dec 2022 1 OT: comparison with other treatment2 CT: study uses combined treatment Favors zinc Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit